Back to Search
Start Over
Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients.
- Source :
-
Pharmacogenomics [Pharmacogenomics] 2020 Feb; Vol. 21 (3), pp. 209-219. - Publication Year :
- 2020
-
Abstract
- Aim: To evaluate the clinical benefits of implementing pharmacogenomics testing for Chinese pediatric patients.  Materials &   methods : Based on the drug-gene interactions involved in the Clinical Pharmacogenetics Implementation Consortium guidelines, whole-genome sequencing data from the Chinese Academy of Sciences Precision Medicine Initiative project and the medication data of pediatric patients from a children's hospital, the prevalence of the Chinese population with actionable pharmacogenomic variants was calculated, the prescribing pattern for pediatric patients was analyzed. Results: 37.0% of the drugs involved in the Clinical Pharmacogenetics Implementation Consortium guidelines were used by Chinese pediatric patients, 8.91% inpatients and 0.89% outpatients received at least one pharmacogenomics medication, 1.24% (4803) inpatients and 0.16% (2940) outpatients were estimated to be at high risk of pharmacogenomic-related adverse therapeutic outcomes. Conclusion: Implementing pharmacogenomics testing can improve therapeutic outcomes for many Chinese pediatric patients.
- Subjects :
- Child
Clinical Competence standards
Humans
Prescription Drugs pharmacokinetics
Asian People genetics
Knowledge Bases
Pharmacogenetics standards
Pharmacogenomic Testing methods
Pharmacogenomic Testing standards
Practice Guidelines as Topic standards
Precision Medicine methods
Precision Medicine standards
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8042
- Volume :
- 21
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Pharmacogenomics
- Publication Type :
- Academic Journal
- Accession number :
- 31967514
- Full Text :
- https://doi.org/10.2217/pgs-2019-0153